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Abstract
One mechanism proposed for reducing the risk of calcium renal stones is activation of the calcium-sensing receptor (CaR)
on the apical membranes of collecting duct principal cells by high luminal calcium. This would reduce the abundance of
aquaporin-2 (AQP2) and in turn the rate of water reabsorption. While evidence in cells and in hypercalciuric animal models
supports this hypothesis, the relevance of the interplay between the CaR and AQP2 in humans is not clear. This paper
reports for the first time a detailed correlation between urinary AQP2 excretion under acute vasopressin action (DDAVP
treatment) in hypercalciuric subjects and in parallel analyzes AQP2-CaR crosstalk in a mouse collecting duct cell line (MCD4)
expressing endogenous and functional CaR. In normocalciurics, DDAVP administration resulted in a significant increase in
AQP2 excretion paralleled by an increase in urinary osmolality indicating a physiological response to DDAVP. In contrast, in
hypercalciurics, baseline AQP2 excretion was high and did not significantly increase after DDAVP. Moreover DDAVP
treatment was accompanied by a less pronounced increase in urinary osmolality. These data indicate reduced urinary
concentrating ability in response to vasopressin in hypercalciurics. Consistent with these results, biotinylation experiments
in MCD4 cells revealed that membrane AQP2 expression in unstimulated cells exposed to CaR agonists was higher than in
control cells and did not increase significantly in response to short term exposure to forskolin (FK). Interestingly, we found
that CaR activation by specific agonists reduced the increase in cAMP and prevented any reduction in Rho activity in
response to FK, two crucial pathways for AQP2 translocation. These data support the hypothesis that CaR–AQP2 interplay
represents an internal renal defense to mitigate the effects of hypercalciuria on the risk of calcium precipitation during
antidiuresis. This mechanism and possibly reduced medulla tonicity may explain the lower concentrating ability observed in
hypercalciuric patients.
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Introduction
The incidence of renal calcium stones has risen steadily over the
past 30 years to become the main cause of hospitalization for uro-
nephrologic reasons [1]. Stone formation is associated with an
increased risk of hypertension, bone disease and chronic kidney
diseases [1,2,3].
Urinary saturation may be the most important factor in stone
pathogenesis and is strictly correlated to water reabsorption in the
kidney. The kidney is a key organ regulating both water and
calcium homeostasis, and its ability to sense extracellular calcium
levels in both the urinary filtrate and the interstitial fluid is due to
the extracellular Calcium–Sensing Receptor (CaR), which is
expressed in multiple sites along the nephron [4].
Specifically, CaR protein is expressed in the apical membrane
of the proximal convoluted and proximal straight tubules, at the
basolateral membrane of the medullary and cortical thick
ascending limbs and distal convoluted tubule, in some cells of
the cortical collecting duct and at the apical membrane of the
inner medullary collecting duct [4,5,6].
The apically located CaR in the proximal tubules appears to
directly attenuate parathyroid hormone (PTH)-induced inhibition
of phosphate reabsorption by proximal tubules and inhibits PTH-
dependent phosphate uptake. Activation of distal tubular CaR,
which is located basolaterally, directly inhibits tubular calcium and
magnesium reabsorption. Thus hypercalcemia, in addition to
indirectly increasing renal calcium excretion as a result of lowering
PTH levels, also directly promotes calciuria.
In the collecting duct, CaR is expressed in the apical
membrane, thus implying that they might be activated by urinary
calcium. Evidence in animal models and in cell culture strongly
suggest that activation of CaR expressed in the collecting duct
epithelial cells reduces the expression of the vasopressin-sensitive
water channel aquaporin-2 (AQP2) and thereby the rate of water
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33145reabsorption [7,8,9]. The AQP2 water channel translocates from
intracellular vesicles to the apical membrane in response to an
acute increase in circulating vasopressin. Water exits the cells via
basolateral AQP3 and AQP4 [10,11].
Hypercalciuria is often present in stone formers, probably due
to a combination of genetic predisposition and diet [12,13,14].
High calcium delivery to the collecting duct would be predicted to
limit local AQP-mediated water reabsorption, protecting against
intratubular deposits and stone formation [15,16,17,18]. While
evidence supporting this hypothesis have been provided in cells
and in hypercalciuric animal models, the relevance of this
mechanism in humans is questioned. In fact, while hypercalciuric
animals exhibit extreme hypercalciuria, humans with hypercalci-
uria most often have urine calcium concentrations of around
6 mM, i.e. within the range of human urine pH, and so would
only weakly stimulate CaR (EC50 for calcium of human CaR
around 6 mM at pH 5.5 to 6.5). As a consequence, CaR in
hypercalciuric subjects are expected to be stimulated mainly under
acute vasopressin action when the calcium concentration rises due
to water reabsorption.
A crucial point in this context is therefore to distinguish between
the short-term effect (within minutes) of a rise in luminal calcium
likely occurring during antidiuresis in response to acute vasopres-
sin action on the AQP2-mediated water reabsorption, and the
long-term effect on AQP2 expression in cells chronically exposed
to high luminal calcium. Previous studies in both cell and animal
models have tended to address the latter point.
In order to investigate whether stimulation of the collecting duct
apical CaR exerts a protective effect against intratubular calcium
precipitation in humans, in the present contribution we evaluate
the short-term effect of vasopressin action on AQP2 trafficking in
the presence of high calcium. The work was conducted in parallel
in hypercalciuric patients and in a mouse collecting duct cell line
stably transfected with AQP2 (MCD4) expressing endogenous and
functional CaR [19]. The results obtained support the hypothesis
that in hypercalciuric patients impaired AQP2 targeting to the
membrane due to activation of luminal CaR signaling might
explain the defect in the kidney’s concentrating ability under acute
vasopressin action. The resulting reduced water absorption may be
a renal defense against urinary calcium supersaturation.
Results
Diuresis, electrolytes, urine osmolality and AQP2
excretion evaluations in hypercalciuric patients subjected
to the DDAVP test
24 h urine flow rate were measured in patients (mean age
8.663.9 years) with a past history of hypercalciuria that was
defined by a urinary Ca/creat ratio .0.2 mg/mg on 3 separate
samples obtained during a 24 h period and had been investigated
after presenting with hematuria or nephrolithiasis at the ‘‘Bambino
Gesu `’’ Pediatric Hospital in Rome, Italy.
Patients enrolled in the study (n=53) were seen on a scheduled
outpatient visit where a complete tubular function, including a
DDAVP test was performed. Patients were then reclassified as
hypercalciuric (n=21) or normocalciuric (n=32) based on their
urinary calcium excretion measured on samples obtained during
the DDAVP test. No patient had evidence of acidosis or serum
electrolyte abnormalities. Patient characteristics and the initial
urinary parameters at baseline, before receiving DDAVP are
reported in Table 1. As shown, the two cohorts were well matched
for age, gender, body mass index and presenting symptoms.
Hypercalciuric patients had a significant lower baseline urine
osmolarity suggesting that children with persisting hypercalciuria
had a lower urine concentration ability compared to those that
had normalized their urinary calcium excretion after the initial
diagnosis. No significant difference was found in the 24 h urine
output between the two groups although a trend for a higher urine
output was observed in hypercalciuric patients.
AQP2 excretion was next monitored in response to intranasal
20 mg DDAVP administration. Urinary AQP2 was measured by
ELISA as previously described [20,21,22] in 3 urine samples
collected before and within 2 hours of DDAVP administration
(urine samples were also collected at 3 and 4 hours for electrolyte
measurements).
In normocalciuric children, DDAVP administration resulted in a
significant increase in AQP2 excretion, (from 198,16635,46 fmol/
mgUcreto371,79678,34 fmol/mgUcre,p,0.005).Incontrast,in
hypercalciuric children, baseline AQP2 excretion was high
(356,32656,23 fmol/mg Ucre) and did not significantly increase
after DDAVP administration (337,29648,95 fmol/mg Ucre, n.s.)
(Fig. 1A). ANOVA test, using calciuria as the nominal independent
variable and urine AQP2 (before and after DDAVP admnistration)
as the continuous dependant variable indicates that calciuria
excretion significantly modulates urine AQP2 levels (F-value:4.53;
p=0.036).
To distinguish between the effect of calciuria on basal AQP2
from DDAVP-stimulated response, the Bonferroni/Dunn post hoc
test was used and showed a highly significant effect of urine
calcium concentration on basal AQP2 levels (p=0.0073), but no
significant effect on AQP2 levels following DDAVP stimulation
(Fig. 1B).
The increase in AQP2 excretion after DDAVP treatment was
paralleled by an increase in urinary osmolality (mean values
1057623 mOsm/Kg) consistent with a physiological response to
DDAVP associated with AQP2 insertion into the luminal
membrane of collecting duct epithelial cells (Fig. 2A and B). In
hypercalciurics, DDAVP treatment was accompanied by a less
pronounced increase in urinary osmolality, which remained
relatively low (mean value 926643 mOsm/Kg, Fig. 2A and B;
p,0.005 vs normocalciuric). These data indicate a reduced
urinary concentrating ability in response to vasopressin in
hypercalciuric subjects. The reason for a high baseline AQP2
excretion in hypercalciuric subjects is unclear. Hypothetically,
these observations may reflect higher cell-surface AQP2 expression
at lower vasopressin levels.
The apparent discrepancy of high baseline AQP2 excretion
associated with mild 24 h polyuria might be due to a reduced
cortico-medullary gradient in hypercalciurics. Therefore the
fractional excretion of the principal electrolytes was evaluated in
hypercalciuric vs normocalciuric children at T0 and in the 3 hours
following DDAVP administration, as shown in Table 2. As
expected, the fractional excretion of calcium (FeCa) was
significantly higher in hypercalciurics at all three tested time
points (T0, T1 and T2) in accordance with calcium loss in those
patients. Sodium fractional excretions (FeNa) was not statistically
different between the two groups although a trend for a higher
FeNa was observed in hypercalciuric patients.
CaR signaling activation and AQP2 trafficking in MCD4
cells
For a better evaluation of AQP2 constitutive as well as regulated
trafficking in collecting duct renal cells under CaR activation, we
analyzed the effect of CaR signaling in MCD4 cells stably
expressing AQP2 [20]. We recently demonstrated that these cells
endogenously express functional CaR protein [19]. In fact, in
MCD4, high Ca
2+ (5 mM), gadolinium (Gd
3+) as well as the
specific allosteric modulator of CaR, NPS-R 568 [23] caused a
CaR and AQP2 Interplay
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33145Figure 1. AQP2 excretion during urinary concentration test. For the urinary concentration test, urinary AQP2 excretion and osmolality were
measured on samples obtained hourly after 20 mg intranasal DDAVP administration. AQP2 urinary excretion. (A) In normocalciuric children, DDAVP
administration resulted in a significant increase in urinary AQP2 excretion. Hypercalciuric children had a high basal AQP2 excretion and DDAVP
administration did not result in a significant increase in urinary AQP2 excretion. Data were analyzed by Wilcoxon Signed Rank ANOVA test for paired
non parametric data (*p=0.0023). (B) Comparison of basal AQP2 excretion in hypercalciurics and normocalciurics. patients. In hypercalciurics a
significant higher AQP2 excretion was observed (p=0.036 ANOVA test).
doi:10.1371/journal.pone.0033145.g001
Table 1. Patient characteristics and baseline urinary parameters.
Units Hypercalciuric Normocalciuric p
Patient characteristics
Gender M:F 12:9 20:12 ns
Age Years 8.263.8 8.964.1 ns
Height SDS 0.1260.94 0.4161.02 ns
Weight SDS 0.2760.85 0.7161.55 ns
BMI SDS 0.3060.91 0.7961.82 ns
Hematuria/Nephrolithiasis(*) n 14/7 24/8 ns
Urine output ml/m
2/24 h 11256351 8676400 ns
Baseline urinary parameters
UOsm mOsm/Kg 7136247 8606250 ,0.05
UCreat mg/dl 66645 112672 ,0.01
UUN mg/dl 7776390 11476429 ,0.001
FeNa % 0.6960.49 0.5160.29 ns
FeK % 15.060.12 11.367.3 ns
FeCl % 1.2160.85 0.9560.70 ns
FeCa % 1.9661.09 0.5260.52 ,0.001
UCa/UCreat mg/mg 0.3660.15 0.0860.06 ,0.001
UMg/UCreat mg/mg 0.1760.09 0.1360.07 ns
TRP % 97.062.2 98.262.8 ns
FeUA % 7.364.1 6.262.7 ns
UGluc/UCreat mg/mg 0.0360.04 0.0260.02 ns
UProt/UCreat mg/mg 0.2360.13 0.2060.16 ns
Abbreviations: M=male; F=female; SDS=standard deviation score; UOsm=urine osmolarity, UCreat=urine creatinine, UUN=urine urea nitrogen; FeNa=fractional
excretion of sodium; FeK=fractional excretion of potassium; FeCl=fractional excretion of chloride; FeCa=fractional excretion of calcium; UCa/UCreat=urinary
calcium:creatinine ratio; UMg/UCreat=urinary magnesium:creatinine ratio; TRP=tubular reabsorption of phosphorus; FeUA=fractional excretion of uric acid; UGluc/
UCreat=urinary glucose:creatinine ratio; UProt/UCreat=urinary protein:creatinine ratio.
(*)numbers indicate the presenting symptom or finding.
doi:10.1371/journal.pone.0033145.t001
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expressed is a functional receptor [19].
To evaluate whether CaR signaling might modulate vasopres-
sin-induced AQP2 trafficking, AQP2 accumulation at the plasma
membrane was semi-quantitated by cell-surface biotinylation in
response to the cAMP elevating agent forskolin (FK) under
different experimental conditions. The total amount of AQP2 in
the starting preparation was comparable in each experimental
condition (Fig. 3A, total AQP2).
Exposure to FK caused a significant (nearly fourfold) increase in
cell-surface accumulation of AQP2 (Fig. 3A and 3B). Moreover,
when FK stimulation was performed in the presence of either
5 mM external calcium, or gadolinium or NPS-R 568, the FK-
induced AQP2 membrane accumulation was significantly reduced
with respect to unstimulated cells (Fig. 3A and 3B).
Another interesting result was the observation that, compared
with untreated cells, treatment with either 5 mM calcium or with
CaR agonists (gadolinium or NPS-R 568) resulted in a significant
increase in the cell-surface abundance of AQP2 in the absence of
FK stimulation. This finding suggests that CaR stimulation ‘per se’
causes AQP2 accumulation at the plasma membrane.
In MCD4 cells, since acute exposure to each of the three agents
(high calcium, gadolinium or NPS-R 568) causes an increase in
intracellular calcium [19], cell-surface biotinylation experiments
were performed in parallel in cells treated with a maximal dose of
ATP (100 mM) known to induce increases in intracellular calcium
ion levels via activation of the ATP-gated calcium channels (P2Y)
[24]. The results obtained revealed that short-term exposure of
cells to ATP caused a significant accumulation of AQP2 at the
plasma membrane, comparable to that obtained with FK
Figure 2. Urinary osmolality during DDAVP test. (A) Baseline and maximal urine osmolality after DDAVP test in normocalciuric and
hypercalciuric patients. (B) Urinary osmolality in samples collected hourly after DDAVP administration. In hypercalciurics, DDAVP treatment was
accompanied by a significantly lower increase in urinary osmolality, indicating a reduced urinary concentrating ability in response to vasopressini n
hypercalciuric subjects. The values obtained were compared by one-way Anova and Tukey’s multiple comparison test (*P,0.005, **P,0.001,
***P,0.0001.).
doi:10.1371/journal.pone.0033145.g002
Table 2. Fractional excretion of sodium, chloride, potassium and calcium during DDAVP testing.
Group Baseline 1 hour 2 hours 3 hours
FeNa (%) Hypercalciuric 0,6960,49 0,6060,47 0,6660,47 0,6760,48
Normocalciuric 0,5060,29 0,4760,24 0,5160,51 0,5260,34
FeK (%) Hypercalciuric 15,0612,2 13,666,5 13,769,0 12,769,4
Normocalciuric 11,367,3 14,168,4 13,4613,4 12,667,8
FeCl (%) Hypercalciuric 1,2160,85 1,1160,83 1,1160,81 1,1260,82
Normocalciuric 0,9560,70 1,0360,69 1,0161,01 0,9260,61
FeCa (%) Hypercalciuric 1,7360,78 1,8460,87 1,6960,72 1,5160,47
Normocalciuric 0,5260,52* 0,4760,52* 0,4660,51* 0,4060,51*
Abbreviations:; FeNa=fractional excretion of sodium; FeK=fractional excretion of potassium; FeCl=fractional excretion of chloride; FeCa=fractional excretion of
calcium.
Data are expressed as mean 6 SD;
(*)p,0.0001 Hypercalciuric vs Normocalciuric.
doi:10.1371/journal.pone.0033145.t002
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comparable in each experimental condition indicating that the
increase of biotinylated AQP2 was a consequence of real
translocation to the plasma membrane. Immunolocalization
experiments and analysis by confocal microscopy confirmed that
ATP, as well as either high calcium or NPS-R 568, caused AQP2
relocation to the plasma membrane comparable to that observed
with FK stimulation (Fig. 4 C). The effect was not observed using
the S enantiomer of 568, which is 30- to 100-fold less potent than
the R enantiomer in activating the CaR (Fig. 4 C) [25].
This data supports the hypothesis that intracellular calcium
increase associated with CaR activation promotes AQP2 vesicle
fusion to the plasma membrane. Moreover, FK stimulation did
not result in a significant additional increase in AQP2 abundance
at the plasma membrane.
Extracellular Ca2+ or CaR Agonists reduced forskolin-
induced accumulation of cAMP
Exposure to the cAMP-generating agent FK increased cyclic
nucleotide accumulation (cAMP) by about threefold in MCD4
cells. Interestingly, in MCD4 cells, when FK stimulation was
performed in association with CaR agonists (high external calcium
or gadolinium or NPS-R 568), a strong reduction in cAMP
accumulation was observed (Table 3). Taken together, these data
indicate that CaR-signaling counteracts the effect of FK on cAMP
synthesis, resulting in reduced cAMP levels.
Rho activity in cells exposed to CaR agonists
cAMP-dependent AQP2 trafficking is regulated by several
proteins including small GTPases of the Rho family controlling
cytoskeletal dynamics. RhoA has been shown to be a major
regulator of actin assembly controlling AQP2 trafficking [26,27].
To evaluate whether altered AQP2 trafficking observed in cells
exposed to CaR agonists is associated with changes in Rho
activity, this was measured by Fluorescence Resonance Energy
Transfer (FRET).
To this end, we used the Raichu-RBD probe consisting of
Venus (a brighter version of yellow fluorescent protein YFP) and
cyan fluorescent protein (CFP) moieties separated by rhotekin-
RBD (Fig. 5A). Activation of Rho therefore leads to binding to
rhotekin-RBD, increased separation of the fluorophores and
consequent loss of FRET (Fig. 5A). Activation of Rho led to a
loss in FRET, seen as an increase in the CFP/YFP emission ratio
(FRET ratio). In contrast, Rho inactivation promoted the transfer
of fluorescence from the donor (CFP) to the acceptor (YFP) thus
increasing the signal of FRET.
Figure 3. Effect of CaR signaling on AQP2 trafficking in MCD4 cells. Apical surface biotinylation. (A) MCD4 cells were preincubated with
5m MC a
2+, 300 mMG d
3+ or 10 mM NPS-R 568 then exposed to FK10
24 M or left under control conditions. Apical membrane-expressed AQP2 was
quantitated by apical surface biotinylation. FK-induced AQP2 membrane accumulation was significantly reduced in the presence of CaR agonists. CaR
agonists induced a mild increase in AQP2 membrane expression even in the absence of FK stimulation. The total amount of AQP2 in the starting
preparation was comparable in each experimental condition (total AQP2). (B) Densitometric analysis of the 29 kDa biotinylated AQP2 band. Results
are expressed as mean values 6 SEM. The values obtained in five independent experiments are expressed as percentages of the basal condition. Data
were compared by one-way Anova and Tukey’s multiple comparison test (* P,0.05 relative to ctr, # P,0.05 relative to FK).
doi:10.1371/journal.pone.0033145.g003
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treated with C3 toxin which inactivates Rho proteins via ADP-
ribosylation. As shown in Fig. 5A (on the right), C3 toxin
significantly increased FRET signal consistent with loss of Rho
activity, confirming that this probe is suitable for mechanistic
investigations. FRET experiment results are summarized in
Fig. 5B. Compared to control cells, FK caused a significant
decrease (depicted by an increase in FRET signal) in the amount
of active RhoA, confirming previous findings in renal collecting
duct cells under FK stimulation [27]. Activation of CaR with
gadolinium but not with NPS-R increased basal RhoA activity
with respect to control untreated cells. This finding is in agreement
with our previous observation in MCD4 cells, demonstrating that
gadolinium (and not NPS) induced intracellular calcium oscillation
associated with activation of the Rho-ROCK pathway [19]. Of
note, exposure to either gadolinium or NPS-R 568 prevented the
decrease in RhoA activity in response to FK (Fig. 5B). The data
obtained indicate that activation of CaR signaling in parallel with
FK stimulation alters the overall equilibrium between Rho
activation and Rho inactivation promoted by the cAMP elevating
agent FK [27]. This may contribute to a reduced FK-dependent
AQP2 accumulation on the plasma membrane.
Since it has been shown that RhoA inhibition induces partial
actin depolymerization which facilitates AQP2 accumulation at
the apical plasma membrane of renal cells, the effect of CaR
activation on the polymerization status of the actin cytoskeleton
was next evaluated in MCD4 cells. Cells were stimulated with
forskolin in the presence or absence of CaR agonists. The effect of
each treatment on actin cytoskeleton was visualized by incubation
with phalloidin-conjugated Alexa Fluor
TM-555 (Fig. 6A).
FK stimulation was associated with a partial depolymerization
of the actin cytoskeleton, confirming previous findings obtained in
other renal cell lines [26,27]. Consistent with FRET data, a strong
stabilization of actin cytoskeleton was observed in cells preincu-
bated with Gd
3+ displaying apparently a higher number of stress
Figure 4. Effect of ATP stimulation on AQP2 trafficking in MCD4 cells. (A) MCD4 cells were preincubated with 100 mM ATP or used under
control conditions and then stimulated with FK 10
24 M. The amount of apical AQP2 was quantitated by apical surface biotinylation. ATP caused
AQP2 membrane accumulation comparable to that found in FK treated cells. The total amount of AQP2 in the starting preparation was comparable in
each experimental condition (total AQP2). (B) Densitometric analysis of the 29 kDa biotinylated AQP2 band. Results are expressed as mean values 6
S.E.M. The values obtained in three independent experiments are expressed as percentages of the basal condition. Data were compared by one-way
Anova and Tukey’s multiple comparison test (* P,0.05 relative to ctr.) (C) Immunolocalization of AQP2 and analysis by confocal microscopy. MCD4
cells were grown on permeable support to full confluence fixed and immunostained with antibodies against AQP2. In resting cells, AQP2 was mainly
detectable in sub-apical vesicles (ctr). After FK treatment, AQP2 localized to the apical membrane (FK). A similar apical localization was observed in
cells exposed to 5 mM calcium (Ca
2+) or to NPS-R 568 (NPS R) or to ATP (ATP) treatments. By contrast, no AQP2 redistribution was observed after
exposure to the inactive NPS enantiomer NPS-S (NPS-S).
doi:10.1371/journal.pone.0033145.g004
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33145Figure 5. RhoA activity in cells exposed to CaR agonists. A. Scheme of the Raichu-RBD probe mechanism. Raichu-RBD contains YFP and
CFP separated by rhotekin-RBD (RBD). Active RhoGTP binds RBD, separating the donor (CFP) from the acceptor (YFP) thus reducing FRET. As internal
control MCD4 cells were incubated for 3 hours with C3 toxin (1 mg/ml), which inactivates Rho proteins, and FRET signals was recorded. As shown in
the figure, C3 toxin (1 mg/ml for 3 hours) (n=124) leaded to a ‘closed’ conformation increasing FRET compared to control cells (n=71). B. Rho
activity during CaR activation. RhoA activity was evaluated in MCD4 cells exposed to CaR agonists. MCD4 cells were preincubated with 5 mM
Ca
2+, 300 mMG d
3+ or 10 mM NPS-R 568 for 30 min and then stimulated with 10
24 M FK or analyzed at rest. The amount of active RhoA was evaluated
by FRET using a probe consisting of a Rho-binding domain (RBD) of Rhotekin sandwiched by YFP and CFP (see Methods). In this system, any increase
in RhoA activity results in a decrease in FRET efficiency. In non-treated cells, FK stimulation (n=59) caused a significant decrease in the amount of
active RhoA compared to control conditions (n=51). In cells pretreated with 300 mMG d
3+, RhoA activity was significantly increased (decreased FRET
signal, n=50) compared to control untreated cells. The decrease in RhoA activity in response to FK was prevented in cells preincubated either with
Gd
3+ (n=66) or NPS-R 568 (n=60). Values are expressed as mean 6 SEM Data were compared by one-way Anova and Tukey’s multiple comparison
test (*P,0.05 relative to control).
doi:10.1371/journal.pone.0033145.g005
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3+ or
NPS-R 568 treated cells appeared to attenuate FK-associated actin
depolymerization (Fig. 6A). Semi-quantitative analysis of the
amount of F-actin evaluated with the actin polymerization assay
indicated that forskolin effect on F-actin content is significantly
attenuated when CaR is activated with Gd
3+, calcium and NPS-
(R) (Fig. 6B).
These data, together with cAMP measurements, indicate that
FK-induced AQP2 relocation to the plasma membrane is
attenuated in the presence of CaR agonists.
Discussion
The findings reported in this study indicate that high
concentrations of luminal calcium attenuate short-term vasopres-
sin-induced AQP2 trafficking via activation of the CaR in inner
medullary kidney collecting duct. The data supporting this
conclusion arise both from experiments performed in vitro using
a well-characterized cortical principal collecting duct cell model
(MCD4 cells) and from hypercalciuric patients. Specifically, this
report shows the effect of CaR activation on AQP2 trafficking
Figure 6. Actin cytoskeleton in cells exposed to CaR agonists. A. Visualization of actin cytoskeleton. MCD4 cells were preincubated with
5m MC a
2+, 300 mMG d
3+ or 10 mM NPS-R 568 for 30 min and then stimulated with 10-4 M FK or analyzed at rest. Cells were fixed in PFA and stained
with phalloidin Alexa Fluor-555 to visualize F-actin. Confocal pictures were taken for each experimental condition. Experiments were performed three
times with similar results. B. F-actin quantization by actin polymerization assay. Confluent cells were either left untreated (CTR) or stimulated with
forskolin (FK) or treated as described above with CaR agonists. After staining with TRITC-phalloidin, cells were extracted with cold methanol and the
fluorescence absorbance of extracts was read (540/565 nm). The values obtained were compared by a one-way Anova and Newman-Keuls multiple
comparison test (#P,0.05).
doi:10.1371/journal.pone.0033145.g006
CaR and AQP2 Interplay
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high external calcium on AQP2 expression. In fact, in a previous
work, Bustamante and coworkers [7], using a mouse cortical
collecting duct cell line (mpkCCDcl4), showed that long-term
exposure to increasing concentrations of extracellular calcium, or
treatment with CaR agonists, reduced the accumulation of both
AQP2 mRNA and protein while CaR gene silencing prevented
this effect. The effect on AQP2 expression in mpkCCD cells is in
agreement with the observed decrease in AQP2 protein abun-
dance in hypercalciuric rats [8,9] supporting a direct effect of
luminal calcium on AQP2 expression in collecting duct principal
cells.
In this work, however, we focused our attention on the short-
term effects of vasopressin on AQP2 trafficking in the presence of
high external calcium. We provide in vivo evidence that, in the
hypercalciuric patients evaluated in this study, baseline AQP2
excretion is significantly higher than in normocalciurics. In these
patients, AQP2 excretion did not increase significantly after acute
DDAVP administration, compared to normocalciurics. These
findings, together with the observation that the 24 h urinary
output, as well as the FeNa during the DDAVP test tended to be
higher in hypercalciuric children, suggest the presence of a
moderate urinary concentrating defect in these subjects. Consis-
tent with these results, cell-surface biotinylation experiments in
MCD4 cells revealed that membrane AQP2 expression in
unstimulated cells exposed to CaR agonists was higher than in
control cells and did not increase significantly in response to short-
term exposure to forskolin (FK). Taken together, these data
support the hypothesis that CaR–AQP2 interplay represents an
internal renal defense to mitigate the effect of hypercalciuria on
the risk of calcium precipitation during antidiuresis.
Calcium stones account for up to 80% of kidney stones and
hypercalciuria is the most common metabolic abnormality found
in calcium stone formers [29,30,31]. In TRPV5
2/2 mice,
Renkema and coworkers demonstrated that the risk of supersat-
uration produced by hypercalciuria is attenuated by activation of
apical CaR, resulting in reduced AQP2 expression and higher net
acid secretion though H
+-ATPase [32]. The resulting polyuria and
urine acidification protects against intratubular calcium precipita-
tion.
Although the suggested mechanism linking CaR activation and
AQP2 expression/trafficking is well supported by findings
obtained in cell models and intact animals [5,7,8,17,33] whether
those data may have pathophysiological relevance in humans is
not clear.
Clinical evidence for an effect of luminal calcium on AQP2-
mediated water reabsorption was provided for the first time in our
previous studies in enuretic children [34,35]. Hypercalciuric
enuretic children treated with DDAVP and low calcium diet
reduced hypercalciuria and this resulted in a reduced overnight
urine output and increased nighttime AQP2 excretion and
osmolality [35].
More recent studies, however, have questioned the relevance of
the CaR-AQP2 interplay in humans. The first major criticism is
that there is no good data supporting the idea that patients with
idiopathic hypercalciuria have polyuria [36]. Secondly, luminal
calcium concentrations found in humans with hypercalciuria are
predicted to have only a weak stimulating effect on CaR (EC50 for
calcium of the human CaR is around 6 mM at pH values in the
range of human urine, 5.5 to 6.5) while hypercalciuric animals
exhibit extreme hypercalciuria.
Regarding the first point, the hypercalciuric patients enrolled in
the present contribution are in pediatric age; the prevalence of
children presenting with nephrolithiasis was similar in the two
groups of patients. As far as the second criticism is concerned, CaR
in hypercalciuric subjects is expected to be stimulated mainly
under acute vasopressin action when the calcium concentration
rises due to water reabsorption. The present contribution indeed
analyzes CaR-AQP2 interplay during acute vasopressin action.
Experiments described in the literature [5] on perfused isolated
inner medullary collecting duct segments from rats exposed in the
short term to vasopressin and either 1 or 5 mM calcium in the
luminal bath, demonstrated that higher luminal calcium concen-
trations caused a modest but significant reduction in water
permeability. Indeed, the decline in water permeability was
quantitatively small (about 33%). However, this small amount
might significantly reduce the risk of calcium stone formation.
In fact, in hypercalciuric subjects, a small increase in urine
volume would reduce the risk of solute precipitation. Specifically, if
the urine flow rate doubled during antidiuresis, the calcium
oxalate ion-products would decrease by 4-fold which might be
crucial in reducing the risk of calcium precipitation, as most
calcium stones consist of more than 90% calcium oxalate [37].
This risk appears to be higher during the night, when plasma
vasopressin is higher and the balance between calcium and water
excretion is most distorted in relation to stone risk [38].
In this work, we found that in hypercalciuric children the
reduced kidney concentrating ability in response to vasopressin
can be at least in part explained by the reduced increase in AQP2
trafficking. However, they had significantly higher baseline AQP2
excretion than normocalciurics. The reason for this is unclear: it
might reflect a higher expression of AQP2 in collecting duct
epithelial cells, possibly due to high luminal calcium that in turn
increases intracellular calcium and calcineurin activation in
particular. Calcineurin, a calcium-dependent protein phosphatase,
activates NFATc (Nuclear Factor of Activated T cell) pathways
that have been shown to enhance AQP2 transcription [39].
Alternatively vasopressin levels in hypercalciuric children might be
higher compared to normocalciuric children thus causing an
increase in AQP2 expression. Both possibilities need to be further
investigated.
To explain the apparent discrepancy between higher AQP2
excretion and lower osmolarity in the baseline samples collected in
hypercalciuric patients, an important point to be considered is that
these children tended to have higher excretion of Na in their
urines. This suggests that they may have a moderate defect in the
generation of the cortico-medullary gradient, which is critical for
the production of concentrated urine. Normalization of urine
calcium excretion in the ‘‘normocalciuric’’ cohort, which included
children previously diagnosed with hypercalciuria, indicates that
these tubular characteristics are not necessarily constitutive, and
may represent in some cases functional adaptations, for example to
diet changes.
The renal cortico-medullary osmotic gradient is generated by
sodium reabsorption in the thick ascending limb. Vasopressin
promotes AQP2 insertion in the apical membrane of principal
cells, allowing water to passively flow along this osmotic gradient
(from the tubule lumen to the interstitium). Therefore, both cell-
surface AQP2 abundance and hypertonic medulla are crucial to
maintenance of body water homeostasis.
Of note, all the clinical data in patients found consistent support
in vitro, in the collecting duct cell line MCD4. We show that in
MCD4 cells expressing endogenous functional CaR [19] cell-
surface AQP2 expression in unstimulated cells exposed to CaR
agonists was higher than in control cells and did not increase
significantly in response to FK. This parallels the observation in
humans.
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cAMP in response to FK and prevented the decrease in RhoA
activity in response to FK: both events are predicted to impair
AQP2 relocation to the plasma membrane.
We underline that this is the first report analyzing short-term
AQP2 trafficking in collecting duct principal cells expressing
endogenous and functional CaR in the presence of selective CaR
(NPS-R 568) agonists. Previous data from our lab have already
demonstrated that external calcium reduced AQP2 trafficking in a
rabbit cell line expressing AQP2 (CD8 cells) but a definitive
demonstration that this occurred through CaR signaling was
lacking [33]. Our in vitro data confirm here the complexity of the
molecular machinery fine-tune controlling AQP2 trafficking in the
presence of the extracellular ‘third messenger’ ionized calcium
which appears to serve as a negative regulator of acute vasopressin
action in the collecting duct.
In conclusion, on the basis of the data from hypercalciuric
patients and from MCD4 cells, we provide evidence that, during
acute vasopressin action, luminal CaR activation in the collecting
duct attenuates AQP2 mediated water reabsorption and urinary
concentration in humans, which may reduce the risk of calcium
salt precipitation and nephrolithiasis.
Materials and Methods
Patients and urinary concentration test
Children with a history of hematuria or nephrolithiasis
secondary to hypercalciuria were enrolled in the study at the
Bambino Gesu ` Hospital in Rome. Hypercalciuria was defined by
a urinary Ca/Creat ratio .0.2 mg/mg on 3 separate samples
obtained during the same day. All patients were tested in an
outpatient clinic; a 24 h urine collection was collected prior to the
outpatient visit to evaluate urinary volume. All patients
underwent a 1–deamino–arginine vasopressin (DDAVP) test as
part of their tubular function evaluation. Subjects were thereafter
classified as ‘‘hypercalciuric’’ (n=21) or ‘‘normocalciuric’’
(n=32), based on the mean Ca/creat excretion measured on
the collected urine samples. Therefore, also patients labeled as
‘‘normocalciuric’’ had a history of hypercalciuria; control patients
without a history of hypercalciuria were not enrolled for ethical
reasons Patients with nephrocalcinosis were excluded, as well as
subjects younger than 5 years of age, because intranasal DDAVP
administration and urine sample collections may be unreliable in
these children. Patients were asked to record their dietary intake
and received advice from a professional dietician in order to
achieve similar normal salt intakes (2 mEq/Kg of body weight)
and to drink approximately 1000 ml/m
2/day. For the urinary
concentration test, urinary AQP2 excretion was measured on
samples obtained hourly after 20 mg intranasal administration of
DDAVP.
Patient weight and fluid intake was monitored during the test
and serum electrolytes were checked before initiating the test. All
patients had serum electrolytes within the normal range.
Written informed consent from a parent or legal guardian was
obtained prior to DDAVP testing in all patients. The study was
conducted according to the principles expressed in the Declaration
of Helsinki and was approved by the Ethical Committee of the
Bambino Gesu ` Children’s Hospital (Approval date: November 3,
2004; President of the ethical committee: Prof. Pierpaolo
Mastroiacovo; copy of the approval letter, as well as copies of
informed consent forms are available upon request).
Urine electrolytes and osmolality were measured by the hospital
clinical laboratory with standard, quality-assessed techniques.
Antibodies and reagents
Affinity-purified Anti-rabbit antibodies against C-terminus of
CaR were from Chemicon (www.chemicon.com). Affinity-purified
rabbit polyclonal antibodies against human AQP2 were prepared
as described elsewhere [40].
All chemicals were purchased from Sigma (www.sigmaaldrich.
com). Fura-2-AM was obtained from Molecular Probes (www.
invitrogen.com). NPS-R 568 was a gift from Amgen. Experiments
were performed with a Ringer solution containing (in mM)
140 NaCl, 5 KCl, 1 MgCl2, 1 CaCl2, 5 glucose, 10 N-2-
hydroxyethylpiperazine-N9-2-ethanesulfonic acid (HEPES) (ad-
justed to pH 7.4 with NaOH). In experiments with high Ca2+,
the ion concentration was raised with CaCl2.
u-AQP2 measurements by ELISA (Enzyme –linked –
immunosorbent –assay)
For determination of u-AQP2 excretion, urine samples were
spun at 3,000 rpm for 10 min at 4uC to remove cellular debris in
the presence of the following protease inhibitors: 2 mM phenyl-
methylsulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml pepstatin. u-
AQP2 excretion was measured as previously described by enzyme-
linked immunosorbent assay [41] with some modifications. Briefly,
10 ml of urine sample were diluted to 50 ml in PBS containing
0.01% SDS, placed in a MaxiSorp 96-well microplate (www.
nuncbrand.com) and incubated for 16 hrs at 4uC. In parallel wells,
increasing concentrations (50, 100, 200, 300, 400, 500 and
1,000 pg/50 ml) of a synthetic peptide reproducing the last 15
amino acids of the C-terminal region of the human AQP2 were
incubated as internal standard. Each sample was analyzed in
triplicate. Wells were washed with washing buffer (PBS-0.1%
Tween20) and incubated with a blocking solution of PBS
containing 3% BSA at room temperature for 1 hr. Ten mgo f
affinity-purified anti-AQP2 antibodies were diluted in blocking
solution (final antibody dilution 1:1,000) and 50 ml of the solution
was added to each well and incubated for 3 hrs at 37uC. Wells
were then washed with washing buffer and anti-rabbit IgG
conjugated with horseradish peroxidase (www.sigmaaldrich.com)
was added to each well and incubated for 1 hr at 37uC.
After five washings with washing buffer, 50 ml of the substrate
solution [2,29-azino-bis(3- ethylbenzthiazoline-6-sulfonic acid);
www.sigmaaldrich.com] were added to each well and incubated
for 30 minutes in the dark. Absorbance was measured with a
microplate reader (Model 550, www.bio-rad.com) at 405 nm. u-
AQP2 excretion was expressed as fmol/mg CreU.
Cell culture
Mouse cortical collecting duct MCD4 cells, stably expressing
human AQP2, were generated as described elsewhere [20] and
maintained in DMEM/F12 1:1 supplemented with 5% fetal
bovine serum, 2 mM L-glutamine, 100 i.u./ml penicillin, 100 mg/
ml streptomycin and 5 mM dexamethasone until sub-confluent.
For all experiments, cells were treated with indomethacin
5610
25 M O/N in the culture medium to reduce the basal
cAMP concentration.
Apical surface biotinylation
Cell monolayers were treated with or without CaR agonists for
309 in the presence or in the absence of 10
24 M FK for 10 min in
the culture medium at 37uC.
Filters were then rapidly washed twice in ice-cold EBS buffer for
biotinylation (10 mM triethanolamine, pH9.0, 150 mM NaCl,
1 mM MgCl2, 0.1 mM CaCl2) and the apical side was incubated
with 650 ml of 2.5 mg/ml EZ-link Sulfo NHS-biotin (www.
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twice in ice-cold PBS-CM and unbound biotin was quenched for
10 min in quenching buffer (50 mM NH4Cl in PBS-CM) on ice.
Cells were scraped from filters in 500 ml of lysis buffer (20 mM
TRIS-HCl, pH8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-
100, 0.2% BSA, 1 mM PMSF, protease inhibitor cocktail), and
lysates were sonicated twice for 15 sec and incubated at 37uC for
20 min.Insolublematerialwaspelletedat 13,0006g for10 minand
biotinylated proteins in the supernatants were precipitated for 16 h
with 50 ml of Immunopure Immobilized Streptavidin beads
suspension (www.piercenet.com) under rotation at 4uC. Beads from
each condition were washed three times in complete lysis buffer and
three times in lysis buffer without BSA. Biotinylated proteins were
extracted in 30 ml of NuPAGE LDS Sample buffer (www.
invitrogen.com) with 100 mM DTT, heated at 95uC for 10 min
and resolved on 4–12% NuPAGE gels (www.invitrogen.com).
Gel electrophoresis and Immunoblotting
Cellular proteins (homogenates or subcellular fractions) were
separated on 4–12% NuPAGE Bis-Tris gels under reducing
conditions. Protein bands were electrophoretically transferred to
ImmobilonP membranes (www.millipore.com) for Western blot
analysis, blocked in TBS-Tween containing 3% BSA and
incubated with primary antibodies. Immunoreactive bands were
detected with secondary antibody conjugated to horseradish
peroxidase (HRP). After each step, the membranes were washed
with TBS-Tween. Membranes were developed with SuperSignal
West Pico Chemiluminescent Substrate (www.piercenet.com) and
were exposed to autoradiographic Kodak Biomax XAR film,
(www.sigmaaldrich.com).
Band intensities were quantitated by densitometric analysis
using National Institutes of Health ImageJ (NIH) software.
Immunofluorescence
MCD4 cells were grown on porous filters and used two days
after full confluence. MCD4 cells were preincubated with 5 mM
Ca
2+, or 300 mMG d
3+ or 10 mM NPS-R 568 or with 100 mM
ATP. Untreated cells were exposed to FK 10
24 M or left under
control conditions. Cell monolayers were then fixed with 4% PFA
in PBS for 20 min at RT and washed twice for 5 min in PBS. Cells
were permeabilized with 0.1% TX-100 in PBS for 15 min at RT
followed by additional washes in PBS. Antigen retrieval procedure
was carried out to better expose protein epitopes. Briefly,
monolayers were treated with 0.5% SDS in PBS for 5 min then
washed several times in PBS. Cells were blocked with 1% BSA in
PBS, then the primary antibody (anti- AQP2 affinity purified) was
diluted in PBS-BSA and incubated for 2 h at RT. Bound antibody
was detected with Alexa Fluor 488 conjugated donkey anti-rabbit
IgG antibodies (www.invitrogen.com). All incubations were
performed from both sides of the filters. Filters were excised from
the support, mounted on microscope slides and viewed with a
Leica TCS-SP2 confocal microscope (www.leica-microsystems.
com).
cAMP measurements
Intracellular cAMP accumulation was measured in MCD4 cells
cultured in 96-well plates to confluence (10
6 cells/well) using a
cAMP enzyme immunoassay kit according to the manufacturer’s
protocol (Amersham cAMP Biotrak Enzymeimmunoassay (EIA)
System, www.gelifescience.com).
Cells were left under control conditions or treated with 5 mM
Ca
2+, or 300 mMG d
3+,o r1 0mM NPS-R 568 for 309. Cells were
then stimulated with 10
24 M FK for 20 minutes at 37uC or left
under control conditions. The reaction was stopped by cooling the
96-well plates in ice. Cells were then lysed using lysis buffer
provided in the kit. cAMP levels were reported as %O.D/mg
proteins vs control cells.
Rho Activity Measurement by Fluorescence Resonance
Energy Transfer (FRET)
RhoA activity was measured by FRET as described [40,42].
Briefly, MCD4 cells were transiently transfected with the Raichu-
RBD construct previously described by Yoshizaki et al. [28]
(kindly provided Prof. Matsuda, Osaka University, Japan). ECFP
and EYFP were excited at 430 or 510 nm, respectively;
fluorescence emitted from ECFP and EYFP was measured at
480/30 and 545/35 nm, respectively. FRET from ECFP to EYFP
was determined by excitation of ECFP and measurement of
fluorescence emitted from EYFP. Corrected nFRET values were
determined according to Ritter [43].
Actin polymerization assay
Cells were left untreated or stimulated with forskolin (10–4 M).
Alternatively, cells were either preincubated with CaR agonists, as
previously described in the absence or in the presence of forskolin.
The treatments were stopped by adding 450 ml of 3.7%
paraformaldehyde, 0.1% Triton X-100, 0.25 mM TRITC-phal-
loidin in 20 mM potassium phosphate, 10 mM PIPES, 5 mM
EGTA and 2 mM MgCl2, pH 6.8. After staining for 1 hour the
cells were washed three times with PBS and 800 ml of methanol
were added overnight. The fluorescence (540/565 nm) was read in
a RF-5301PC fluorimeter. The values obtained were normalized
for the total amount of proteins.
Data Analysis. The results of the quantitative variables were
expressed as mean 6 standard error (SE) of the mean, unless
otherwise indicated. Statistical analysis were performed by one-
way ANOVA. Bonferroni/Dunn post hoc test was used to
evaluate the effect of calciuria on AQP2 excretion in the
enrolled patients.
P-values,0.05 were considered statistically significant. Data
were obtained from at least three independent experiments in each
experimental condition.
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